ASH: Argenx cues up a second use for efgartigimod
pharmaphorum
DECEMBER 12, 2022
Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – primary immune thrombocytopenia (ITP) – thanks to new data reported at the ASH annual meeting. Analysts have said that Vyvgart could reach blockbuster sales of $2 billion or more if available in a subcutaneous version.
52 
Let's personalize your content